Comparison of the effectiveness of duloxetine in depressed patients with and without a family history of affective disorders in first-degree relatives.
Comparison of the effectiveness of duloxetine in depressed patients with and without a family history of affective disorders in first-degree relatives.
复制标题
度洛西汀对有和无一级亲属情感障碍家族史的抑郁症患者的疗效比较
DOI：
10.11919/j.issn.1002-0829.215080
复制
发表时间：
2015-08-25
期刊：
影响因子：
--
通讯作者：
Chen W
中科院分区：
文献类型：
--
作者：
Wang S;Qian M;Zhong H;Song G;Lu M;Feng R;Zhang L;Ni J;Chen W
目前尚不清楚是否有情感障碍的阳性家族史预示着抗抑郁药物治疗抑郁症的有效性。评估情感性障碍家族史与度洛西汀治疗抑郁症疗效的关系。77名抑郁症患者（根据《国际疾病分类》第10版的定义，ICD-10）参加了这项研究，并接受了标准剂量的度洛西汀治疗12周。在这些患者中，37人有一级亲属情感性障碍家族史，40人没有。汉密尔顿抑郁量表（HAMD-17）、汉密尔顿焦虑量表（HAMA）、副作用量表（SERS）、斯奈斯-汉密尔顿愉悦量表（SHAPS）和贝克抑郁量表（BDI）于基线和入组后第2、4、6、8、12周末进行评估。采用重复测量方差分析和logistic回归分析情感性障碍家族史与度洛西汀疗效之间的关系。情感性障碍家族史阳性的患者发病年龄较早，病程较长，精神焦虑程度较高，快感缺乏更为突出。反复测量方差分析显示，在12周内，抑郁症的严重程度有了显著改善，但两组之间改善的幅度和速度没有差异。75.7%有情感性障碍家族史的患者和77.5%无情感性障碍家族史的患者认为治疗有效（即基线HAMD-17总分下降≥50%）（X2=0.04, p=0.850）。情感性障碍的家族史与度洛西汀急性治疗抑郁症的有效性无关。
It remains unclear whether or not a positive family history of affective disorders predicts the effectiveness of antidepressant treatment of depression. Assess the relationship of a family history of affective disorders to the efficacy of duloxetine in the treatment of depressive disorder. Seventy-seven patients with depressive disorder (as defined by the 10th edition of the International Classification of Diseases, ICD-10) were enrolled in the study and treated with standard doses of duloxetine for 12 weeks. Among these patients 37 had a family history of affective disorder in first-degree relatives and 40 did not. The Hamilton Depression rating scale (HAMD-17), Hamilton Anxiety rating scale (HAMA), Side Effects Rating Scale (SERS), Snaith-Hamilton Pleasure Scale (SHAPS), and Beck Depression Inventory (BDI) were assessed at baseline and at the end of the 2nd, 4th, 6th, 8th, and 12th week after enrollment. Repeated measures analysis of variance and logistic regression were used to analyze the association between a family history of affective disorders and the efficacy of duloxetine. Patients with a positive family history of affective disorders had an earlier age of onset, a longer duration of illness, a higher level of psychic anxiety, and more prominent anhedonia. Repeated measures analysis of variance showed a significant improvement in the severity of depression over the 12 weeks but no differences in the magnitude or speed of improvement between the two groups. Treatment was considered effective (i.e., drop in baseline HAMD-17 total score of ≥50%) in 75.7% of those with a family history of affective disorders and in 77.5% of those without a family history (X2=0.04, p=0.850). Family history of affective disorders is not associated with the effectiveness of duloxetine in the acute treatment of depressive disorder.